Approval · Notice of Compliance 13818 · 2012
ULTIVA: Notice of Compliance 13818
Issued November 7, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13818
- Date
- November 7, 2012
- Company
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- manufacturer name change
- Therapeutic class
- Opioid domponent to anesthesia
Products in this notice
Medicinal ingredients
- REMIFENTANIL HCL 1 MG per VIAL
- REMIFENTANIL HCL 2 MG per VIAL
- REMIFENTANIL HCL 5 MG per VIAL